CBD Reduces Enlarged Mitochondria in Barth Syndrome Cells

Can CBD help damaged mitochondria regain a more normal shape, and would that mean they have been repaired? A new University of Waterloo study offers an encouraging answer to the first question while showing why the second requires more care.

In a study accepted by Biochemical and Biophysical Research Communications, researchers found that cannabidiol reduced abnormal mitochondrial enlargement in patient-derived cells used to investigate Barth syndrome.¹ However, CBD did not significantly restore the mitochondria’s internal membrane folds. The result points toward a specific biological effect rather than a complete correction of the disease.

That distinction makes the research useful. Understanding which parts of a cellular problem respond to CBD, and which remain unchanged, can help researchers design more informative experiments and identify where additional interventions might be needed.

Why Mitochondrial Structure Matters in Barth Syndrome

Mitochondria help cells convert nutrients into usable energy. Their internal membranes contain folds called cristae, which accommodate important components of the energy-producing machinery. Their organization matters alongside the overall size and number of mitochondria.

Barth syndrome is a rare genetic disorder involving loss of function in tafazzin, an enzyme that remodels a specialized fat called cardiolipin. Cardiolipin helps support mitochondrial membranes. When its amount and composition become abnormal, mitochondrial organization and function can suffer.

The condition can affect heart muscle, skeletal muscle, and immune cells. The present research focused on B-lymphoblastoid cells, laboratory cell lines derived from B lymphocytes, a type of immune cell. These provide a manageable model for examining cellular abnormalities associated with the disorder.

Think of a mitochondrion as a workshop whose internal work surfaces have become disorganized. Returning the building to its usual dimensions would be a meaningful change, but it would not automatically rearrange everything inside. The new findings make that distinction visible.

How Researchers Tested CBD in Patient-Derived Cells

The team used cells originally obtained from boys aged seven to ten, with and without Barth syndrome. The cells had been transformed using Epstein-Barr virus so they could be maintained as laboratory cell lines. They were not fresh immune cells being observed inside patients.

Researchers exposed the cells to either 1 micromolar CBD or a vehicle control for 96 hours. The CBD reagent had a reported purity of at least 98%. Transmission electron microscopy provided detailed images of mitochondrial structure, while protein measurements examined regulators of mitochondrial division and fusion.

The microscopy analysis included three Barth syndrome cell lines in each treatment condition, three healthy control lines receiving vehicle, and two healthy lines receiving CBD. Researchers averaged observations within each donor-derived sample before calculating group results. This matters because many mitochondrial images do not represent an equally large number of independent donors.

Some untreated control measurements had appeared in an earlier study, with samples prepared together as part of a larger experiment. Additional images were acquired for the present analysis. That shared experimental background should be recognized when judging how much independent replication the findings provide.

What CBD Changed in Barth Syndrome Cells

Without CBD, mitochondria in the Barth syndrome cells had an average cross-sectional area approximately 2.7 times that of healthy controls. CBD reduced the average area to a level comparable with untreated healthy cells.

The clearest numerical result concerned unusually large mitochondria, defined as having a cross-sectional area greater than one square micrometer. Their share fell from 18.2% in untreated Barth syndrome cells to 2.0% after CBD treatment, an approximately 89% relative reduction.

That figure describes the frequency of enlarged mitochondria in this experiment. It does not mean that CBD repaired 89% of mitochondrial damage or improved patients’ health by that amount.

How CBD Might Influence Mitochondrial Division

Mitochondria continually change through division, called fission, and joining, called fusion. A protein named DRP1 helps carry out division. Chemical modifications to this protein can influence its activity.

In untreated Barth syndrome cells, phosphorylation at DRP1’s Ser637 site was almost 2.9 times higher than in healthy controls. This modification is associated with inhibition of mitochondrial division. CBD reduced it close to control levels, consistent with releasing a brake on fission.

However, consistency is not proof of causation. The researchers measured a protein modification and observed smaller mitochondria; they did not directly establish that changing this modification was necessary for CBD’s effect.

A useful next experiment would interfere with the proposed DRP1 pathway and test whether CBD still reduces enlargement. That would help distinguish a mechanism driving the change from a molecular signal that accompanies it.

Why Smaller Mitochondria Do Not Mean Complete Repair

The researchers’ earlier 2026 CBD study reported improvements in cell growth, cardiolipin abundance, and mitochondrial respiration in related Barth syndrome cell models. It did not fully normalize cardiolipin’s fatty-acid composition. Those functional findings belong to the earlier work, rather than being new measurements in the current paper.

Together, the studies suggest a useful hypothesis: restoring the quantity of a membrane component may not be enough if its composition remains abnormal. The current paper’s persistent cristae defects support investigating that possibility, without establishing it conclusively.

This offers a broader lesson for cannabinoid research. “Mitochondrial health” is not a single measurement. Size, internal architecture, membrane chemistry, and energy production can respond differently. An intervention may improve one feature while leaving another unresolved.

Earlier preclinical CBD research in Leigh syndrome, published in 2024, also explored mitochondrial disease, reporting benefits in mouse models and patient-derived cells. It provides background for this research direction, but involves a different disorder and proposed mechanism. It cannot establish that CBD benefits people with Barth syndrome.

What the Findings Mean for CBD Product Claims

The experiment tested a defined CBD reagent at a controlled concentration. It did not test commercial oils, gummies, mixed cannabis extracts, or a dosing schedule for patients. A concentration in culture medium cannot be converted directly into an oral dose.

MyCannabis coverage of high-purity CBD production offers relevant manufacturing context. A clearly characterized ingredient helps define what an experiment tests, but purity alone cannot establish therapeutic effectiveness.

Similarly, recent coverage of CBD delivery research highlights why formulation deserves separate investigation. The wider research question is not simply whether CBD can affect cells, but whether an appropriate preparation can produce a useful, sustained effect in the relevant tissue.

This paper therefore provides no basis for recommending a retail CBD product for Barth syndrome. Its value lies in identifying a measurable response that further research can test.

The Next Questions for CBD and Mitochondrial Research

The small number of donor-derived lines, transformed cell model, and single concentration and exposure period limit generalization. Microscopy also captures sections at particular moments rather than directly recording mitochondrial division over time.

Three next steps would make the evidence substantially more informative:

• Replicate the findings across more donors and additional disease-relevant cell types.
• Test whether disrupting DRP1 regulation prevents the reduction in mitochondrial enlargement.
• Measure structure and function together across concentrations and exposure periods.

The paper also discloses cannabinoid-related patents and a corresponding author’s shareholding in Akseera Pharma. The authors state that the company did not fund or conduct this work. Independent replication would strengthen confidence in the findings.

The encouraging outcome is a specific, testable observation: CBD changed abnormal mitochondrial size without fully restoring internal architecture. The next question is whether that structural improvement produces durable functional benefits in more representative models, and what additional changes are needed for a more complete recovery.

References:

¹ Chan, J. Z., Groh, M., Musa, M., Sciaini, G., & Duncan, R. E. (2026). Cannabidiol abrogates the atypical enlargement of mitochondria in Tafazzin-deficient B-lymphoblastoid cells. Biochemical and Biophysical Research Communications. Advance online publication. https://doi.org/10.1016/j.bbrc.2026.154849